key: cord-0974027-tlsxc6es
authors: Papenburg, Jesse; Cheng, Matthew P; Corsini, Rachel; Caya, Chelsea; Mendoza, Emelissa; Manguiat, Kathy; Robbin Lindsay, L; Wood, Heidi; Drebot, Michael A; Dibernardo, Antonia; Zaharatos, Gerasimos; Bazin, Reneé; Gasser, Romain; Benlarbi, Mehdi; Gendron-Lepage, Gabrielle; Beaudoin-Bussières, Guillaume; Prévost, Jérémie; Finzi, Andrés; Ndao, Momar; Yansouni, Cedric P
title: Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay
date: 2021-04-30
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab220
sha: a4af14b02d464b5a158867c013de25621adb984c
doc_id: 974027
cord_uid: tlsxc6es

BACKGROUND: SARS-CoV-2 surrogate neutralization assays that obviate the need for viral culture offer substantial advantages regarding throughput and cost. The cPass SARS-CoV-2 Neutralization Antibody Detection Kit (Genscript) is the first such commercially available assay, detecting antibodies that block RBD/ACE-2 interaction. We aimed to evaluate cPass to inform its use and assess its added value compared to anti-RBD ELISA assays. METHODS: Serum reference panels comprising 205 specimens were used to compare cPass to plaque-reduction neutralization test (PRNT) and a pseudotyped lentiviral neutralization (PLV) assay for detection of neutralizing antibodies. We assessed the correlation of cPass with an ELISA detecting anti-RBD IgG, IgM, and IgA antibodies at a single timepoint and across intervals from onset of symptoms of SARS-CoV-2 infection. RESULTS: Compared to PRNT-50, cPass sensitivity ranged from 77% - 100% and specificity was 95% - 100%. Sensitivity was also high compared to the pseudotyped lentiviral neutralization assay (93% [95%CI 85-97]), but specificity was lower (58% [95%CI 48-67]). Highest agreement between cPass and ELISA was for anti-RBD IgG (r=0.823). Against the pseudotyped lentiviral neutralization assay, anti-RBD IgG sensitivity (99% [95%CI 94-100]) was very similar to that of cPass, but overall specificity was lower (37% [95%CI 28-47]). Against PRNT-50, results of cPass and anti-RBD IgG were nearly identical. CONCLUSIONS: The added value of cPass compared to an IgG anti-RBD ELISA was modest.

Use cases for serological testing for prior exposure to Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) have been reviewed in detail 1, 2 . Despite a rapid increase in the number and availability of serological assays detecting SARS-CoV-2 antibodies, critical knowledge gaps remain regarding the magnitude and kinetics of the correlation between results of these assays and the presence of neutralizing antibodies.

Only a subset of antibodies against a specific antigen can neutralize viral replication.

Assays that measure neutralizing antibody levels, such as plaque reduction neutralization tests (PRNT) and microneutralization methods, provide essential data; these assays can help validate candidate diagnostic tests and define serological correlates of immunity. However, functional cell-based assays of SARS-CoV-2 neutralization can only be performed in a Biosafety Level 3 (BSL-3) laboratory, which is labour-intensive, costly, and limits testing throughput. Pseudotyped viruses have been developed that incorporate the Spike protein of SARS-CoV-2 and can be cultivated in BSL-2 conditions 3 . Assays incorporating such pseudotyped viruses provide a functional assessment of the host neutralizing antibody responses as an alternative to using the wild-type virus [4] [5] [6] [7] . By contrast, surrogates of neutralization that bypass the need for viral culture would offer substantial advantages in terms of throughput, cost, and scalability. At least one direct ELISA assay detecting antibodies to the whole Spike protein has received regulatory approval in Europe for assessment of neutralizing antibodies 8 . Further, several groups have proposed blocking assays, leveraging different signal detection methods to quantify the presence of host antibodies that can block the interaction of the SARS-CoV-2 Spike protein with human ACE-2 receptor 9-12 . A c c e p t e d M a n u s c r i p t 6 On 6 Nov 2020, the FDA issued an emergency use authorization (EUA) for the cPass SARS-CoV-2 Neutralization Antibody Detection Kit (cPass; Genscript, Piscataway, NJ) 13 , which is the first such surrogate neutralization assay to be commercially available. The cPass uses a blocking ELISA format with human ACE-2 receptor molecules coated on an ELISA plate 9, 14 . Human sera pre-incubated with labelled epitopes of the receptor binding domain (RBD on S1 proteins) are then transferred to the plate. This blocking ELISA serves as a surrogate assay to inform on the capacity of human sera to block the interaction between the Spike fusion protein (through its RBD) and its cellular receptor ACE-2.

The objective of this study was to inform the use of the cPass and assess its added value compared to laboratory-developed anti-RBD ELISA assays by performing an evaluation using a variety of well characterised specimens. A number of reference panels were utilized to better understand the ability of the cPass assay to detect significant titres of neutralizing antibodies assessed by culture-based reference methods. We compared cPass to PRNT and to a pseudotyped virus neutralization assay. We also sought to describe the correlation of cPass with a laboratory-developed indirect ELISA detecting anti-RBD IgG, IgM, and IgA antibodies at a single timepoint and across different timeframes among specimens collected at a known interval from onset of symptoms of SARS-CoV-2 infection.

A c c e p t e d M a n u s c r i p t 7

All work was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate institutional board. Convalescent plasmas were obtained from donors who consented to participate in this research project at Héma- cPass testing was performed, an REB exemption was granted on the basis that this work was considered to be a laboratory quality improvement project with no risk to participants.

We assembled several well-characterised SARS-CoV-2 serological specimen panels to assess the performance characteristics of the cPass culture-free neutralization antibody detection kit (Table 1) 15 ; and two separate curated panels from Héma-A c c e p t e d M a n u s c r i p t 8 Québec and CR-CHUM. The later panels comprised convalescent plasma donors (confirmed SARS-CoV-2 infection and complete resolution of symptoms for at least 14 days) with either single timepoint or longitudinal follow-up. In addition to panels using neutralization assays as the reference standard, we assembled 136 specimens from healthy blood donors who tested negative for the presence of anti-SARS-CoV-2 antibodies by both a lab-developed anti-RBD IgG ELISA and a commercial assay detecting anti-nucleocapsid antibodies (Abbott Architect SARS-CoV-2 IgG Assay). These specimens, collected between 25 May and 9 July 2020, were acquired to help assess the ability of the cPass assay to detect specimens that test negative by other serological methods.

All specimens and controls were processed according to the manufacturer's instructions (including a 10X dilution factor of the primary specimen) and were tested in triplicate. The percentage of inhibition calculation was based on the mean of OD for each triplicate. A cut-off of 30% inhibition of RBD-ACE2 binding was used to determine the presence of neutralizing antibodies, based on the manufacturer's instructions for use.

Neutralizing antibodies were detected via either assessment of plaque reduction neutralization titres using wild-type SARS-CoV-2, or by determining the neutralization halfmaximal inhibitory dilution (PLV ID50) or the neutralization 80% inhibitory dilution (PLV ID80) of pseudotyped lentiviral vector 16 .

Assessment of plaque-reduction neutralization using wild-type SARS-CoV-2 was performed at the Public Health Agency of Canada's National Reference Laboratory for Microbiology. Briefly, heat-inactivated serological specimens were diluted 2-fold from 1:10 A c c e p t e d M a n u s c r i p t 9 to 1:320 in DMEM supplemented with 2% FBS and challenged with an equal volume of 50 plaque forming units (PFU) of SARS-CoV-2 (hCoV-19/Canada/ON_ON-VIDO-01-2/2020, EPI_-ISL_425177), which were titrated by plaque assay, for final dilutions of 1:20 to 1:640 17 . After 1 hour of incubation at 37°C and 5% CO2, the sera-virus mixtures were added to 12well plates containing Vero E6 cells at 90% to 100% confluence and incubated at 37°C and 5% CO2 for 1 hour. After adsorption, a liquid overlay comprising 1.5% carboxymethylcellulose diluted in MEM supplemented with 4% FBS, L-glutamine, nonessential amino acids, and sodium bicarbonate was added to each well and plates were incubated at 37°C and 5% CO2 for 72 hours. The liquid overlay was removed, and cells were fixed with 10% neutral-buffered formalin for 1 hour at room temperature. The monolayers were stained with 0.5% crystal violet for 10 minutes and washed with 20% ethanol. Plaques were enumerated and compared to controls. The highest serum dilution resulting in 50% and 90% reduction in plaques compared with controls were defined as the PRNT-50 and PRNT-90 endpoint titres, respectively. PRNT-50 titres and PRNT-90 titres ≥1:20 were considered positive for SARS-CoV-2 neutralizing antibodies. Pseudoviral neutralization testing was performed as previously described 16 . Briefly, target cells were infected with single-round luciferase-expressing lentiviral particles. HEK 

Specimens were analysed with a laboratory-developed indirect ELISA detecting anti-RBD IgG, IgM, and IgA as previously described 16, 18 . Recombinant SARS-CoV-2 S RBD proteins (or OC43 S RBD proteins) (2.5 mg/ml), or bovine serum albumin (BSA) (2.5 mg/ml) as a negative control, were prepared in PBS and were adsorbed to plates (MaxiSorp; Nunc) overnight at 4°C. Coated wells were blocked with blocking buffer (Tris-buffered saline, 0.1% Tween-20, 2% BSA) for 1h at room temperature. Wells were washed four times with washing buffer (Tris-buffered saline, 0.1% Tween20). CR3022 mAb (50ng/ ml) or sera from SARS-CoV-2-infected or uninfected donors (1/100; 1/250; 1/500; 1/1000; 1/2000; 1/4000) were diluted in blocking buffer and incubated with the RBD-coated wells for 1h at room temperature. Plates were washed four times with washing buffer followed by incubation with secondary Abs (diluted in blocking buffer) for 1h at room temperature, followed by four washes. HRP enzyme activity was determined after the addition of a 1:1 mix of Western Lightning oxidizing and luminol reagents (Perkin Elmer Life Sciences).

A c c e p t e d M a n u s c r i p t 11 Light emission was measured with a LB942 TriStar luminometer (Berthold Technologies).

Signal obtained with BSA was subtracted for each serum and were then normalized to the signal obtained with CR3022 mAb present in each plate. Alternatively, the signal obtained with each serum on OC43 RBD was normalized with the signal obtained with 4.3E4 mAb present in each plate. The seropositivity threshold was established using the following formula: mean RLU of all COVID-19 negative sera normalized to CR3022 (or 4.3E4) + (3 standard deviations of the mean of all COVID-19 negative sera).

The Abbott SARS-CoV-2 IgG assay (Abbott Laboratories, USA) detecting antinucleocapsid IgG was performed on the Architect i2000sr platform according to the manufacturer's instructions. Specimens were thawed on the day of testing and were centrifuged 10,000g for 10 min prior to each run.

The diagnostic accuracy of the cPass surrogate viral neutralization assay was estimated compared to different reference standards (WT PRNT-50; WT PRNT-90; PLV ID50; PLV ID80, Live Virus (CPE), and VSV-PV). Sensitivities and specificities are presented with 95% confidence intervals (95% CI). The effect of varying the cut-off value (i.e., % inhibition of RBD-ACE2 binding) for cPass positivity on the diagnostic accuracy of the cPass against a PLV ID50 reference standard was investigated using a receiver operating characteristic (ROC) curve. The association between cPass % inhibition and results obtained using laboratory-developed ELISA detecting anti-S-RBD IgG, IgM, and IgA, or against PLV ID50 are presented in scatterplots with the strength of these associations informed by Pearson correlation. Lastly, among specimens from individuals with a known interval from onset of SARS-CoV-2 infection symptoms and repeated testing over time, spaghetti plots were A c c e p t e d M a n u s c r i p t 12 created to investigate any change in signal over time for the cPass and direct anti-S-RBD ELISA with statistical significance assessed using the Wilcoxon matched-pairs signed-rank test (p<0.05 denoted by *). Statistical analyses were performed using R version 3.5.2 (R Core Team, Vienna, Austria).

Diagnostic accuracy for the detection of anti-SARS-CoV-2 neutralizing antibodies, and the impact of using different reference standards Table 1 shows the estimated diagnostic accuracy of the GenScript cPass neutralization antibody detection assay among well characterised specimen panels, according to different reference standards. Among various reference standards, results from the same PLV ID50 assay were available for all panels except the WHO panel, and this was used to estimate aggregate diagnostic accuracy values across several panels.

Overall, cPass had sensitivity ranging 77% -100% and specificity of 95% -100% compared to the reference standard of a 50% plaque reduction neutralization using SARS-CoV-2 viral culture (WT PRNT-50) ( Table 1) . Changing the WT PRNT-50 cut-off titre from 1:20 to 1:50 had minimal impact on specimen categorization. Sensitivity remained very high compared to the reference standard of a neutralization half-maximal inhibitory dilution using a validated pseudotyped lentiviral vector neutralization assay (PLV ID50) with a cut-off titre of 1:50, but specificity was lower than that compared to WT PRNT-50, ranging from 17-70% (Table 1) . (Tables 1 and 2 Among paired specimens from the same individual collected at a known interval from SARS-CoV-2 diagnosis, aggregate results of both cPass and direct anti-RBD IgG ELISA did not change between 6 weeks and 10 weeks after diagnosis (p=1.00 and 0.104, respectively, by the Wilcoxon signed rank test) (Figure 3 ). In contrast, ELISA readouts decreased significantly over the same timeframe for direct anti-RBD IgM (p=0.0058) and IgA (p=0.0012).

Among 136 specimens from healthy blood donors who tested negative for the presence 

Rapid and high throughput surrogates for PRNT or pseudovirus neutralization assays that bypass the need for cell culture are awaited with the belief that they will offer additional information to that from standard direct immunoassays, such as a higher specificity for neutralizing antibodies. The cPass SARS-CoV-2 Neutralization Antibody Detection Kit (cPass) is the first such assay to be commercially available and to receive FDA EUA in the U.S. An evaluation of a cPass prototype, using a cut-off value of 20% inhibition, found that it could provide a high-throughput screening tool for confirmatory PRNT testing 19 . The results of the current evaluation support the ability for cPass to detect neutralizing antibodies to SARS-CoV-2, although specificity varied considerably depending on the reference assay used. Our data also extend these findings by showing that cPass performed similarly to a nonblocking anti-RBD ELISA among varied well characterised specimen panels. Table 1 ) appears related to the choice of 30% RBD-ACE2 binding inhibition cut-off recommended by the manufacturer, which may result in false negative results for specimens with low titres of neutralizing antibodies. Among all specimens evaluated, however, reducing the inhibition cut-off to 20% would have a minimal impact on overall sensitivity and yield substantial reduction in overall specificity compared to PLV ID50 (Supplemental Figure 1 ).

Our results do not suggest that the cPass assay, targeting only RBD-ACE2 blockade, would miss a substantial proportion of patients with neutralizing antibodies that target non-RBD A c c e p t e d M a n u s c r i p t 16 epitopes 20-22 . This may be because neutralizing antibodies to non-RBD epitopes usually occur concomitantly with anti-RDB neutralizing antibodies, instead of in isolation.

By contrast, estimates of the specificity of cPass for the detection of anti-SARS-CoV-2 neutralizing antibodies were contingent of the reference standard used (Table 1 ). There was near-perfect negative agreement with WT PRNT-50 using a cut-off titre of either 1:20 or 1:50. However, negative agreement was much lower when cPass was compared to either PLV ID50 or WT PRNT-90. Our data raise the unresolved questions of which reference technique (i.e., wild-type or pseudotyped live viral culture), level of stringency (e.g., 50%

inhibition of infection vs 80%, 90%, etc), and cut-off titre (e.g., 1:20 vs 1:50) best represent serocorrelates of protection to SARS-CoV-2, or other relevant applications. Moreover, protocols can vary widely for the same technique across different laboratories, requiring caution in the interpretation of these and other data 23 . In the current manuscript, PLV ID50 with a cut-off titre of 1:50 was used as the overall comparator because it was the technique applied to all available specimen panels except the 5-member panel from WHO. Our results must be interpreted in context with this potential source of bias. However, we note that this technique has been employed by other groups and thus offers a high degree of generalizability with other results 24,25 .

The cPass assay detected all specimens with positive WT PRNT-90 titres, with a significant proportion of false positives (Figure 1) . A 50-fold dilution of the 16 primary specimens with WT PRNT-50 titres ≥1:20 increased specificity for detecting those with WT PRNT-90 titres ≥1:20 from 11% (95% CI 0-48) to 100% (95% CI 66-100). This may represent a useful approach for using the cPass assay to identify blood specimens with positive WT PRNT-90 titres, which has been proposed as a desirable characteristic for sera used in convalescent plasma trials by some regulatory agencies. (Table 1) . Taken together, these results suggest that a positive cPass result in the context of a remote infection may not accurately predict the presence of neutralizing antibodies. In addition, specificity of the cPass may be affected by the possibility that part of the inhibition of binding in the cPass assay could be due to steric hindrance by the abundant anti-Spike antibodies of the IgG isotype rather than by true neutralization (as occurs in vivo).

The results of the current evaluation demonstrate the ability of cPass to detect blood specimens with anti-SARS-CoV-2 neutralizing antibodies. However, the added value of cPass compared to an IgG anti-RBD ELISA was modest. 

Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A Narrative Review

SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect

A serological assay to detect SARS-CoV-2 seroconversion in humans

Current status on the development of pseudoviruses for enveloped viruses

Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses

Liaison(R) SARS-CoV-2 S1/S2 IgG Brochure -A quantitative assay with correlation to neutralizaing antibodies

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay. medRxiv

A simple protein-based surrogate neutralization assay for SARS-CoV-2

Coronavirus (COVID-19) Update: FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection

cPass(TM) SARS-CoV-2 Neutralization Antibody Detection Kit -Instructions for use

First WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

We thank the convalescent plasma donors who participated in this study; the Héma-Québec team involved in convalescent donor recruitment and plasma collection; the staff members of the CRCHUM BSL3 Platform for technical assistance; Stefan Pöhlmann (Georg-August University, Germany) for the plasmid coding for SARS-CoV-2 S.

A c c e p t e d M a n u s c r i p t 21